Direct-to-Consumer Advertising of Pharmaceuticals as a Matter of Corporate Social Responsibility?

Direct-to-consumer advertising (DTCA) of prescription drugs has been a heavily contested issue over the past decade, touching on several issues of responsibility facing the pharmaceutical industry. Much research has been conducted on DTCA, but hardly any studies have discussed this topic from a corp...

Full description

Saved in:  
Bibliographic Details
Authors: van de Pol, Pepijn K. C. (Author) ; de Bakker, Frank G. A. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: Springer Science + Business Media B. V 2010
In: Journal of business ethics
Year: 2010, Volume: 94, Issue: 2, Pages: 211-224
Further subjects:B direct-to-consumer-advertising (DTCA)
B consumer safety
B Pharmaceutical Industry
B Corporate social responsibility (CSR)
Online Access: Presumably Free Access
Volltext (JSTOR)
Volltext (lizenzpflichtig)
Description
Summary:Direct-to-consumer advertising (DTCA) of prescription drugs has been a heavily contested issue over the past decade, touching on several issues of responsibility facing the pharmaceutical industry. Much research has been conducted on DTCA, but hardly any studies have discussed this topic from a corporate social responsibility (CSR) perspective. In this article, we use several elements of CSR, emphasising consumer autonomy and safety, to analyse differences in DTCA practices within two different policy contexts, the United States of America and the European Union (EU). Doing so results in an alternative analysis of the struggle between proponents and opponents of DTCA from a CSR perspective, adding an alternative view on this debate.
ISSN:1573-0697
Contains:Enthalten in: Journal of business ethics
Persistent identifiers:DOI: 10.1007/s10551-009-0257-z